1. Eusebi, LH. Black, CJ. Howden, CW. Ford, AC. Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. 2019,1-13. doi: 10.1136/bmj.l6483
2. Vandenberghe, A. Schol, J. Van den Houte, K. Masuy, I. Carbone, F. Tack, J. Current and emerging therapeutic options for the management of functional dyspepsia. 2019, 365-376. https://doi.org/10.1080/14656566.2019.1707805
3. Miwa, H. Nagahara, A. Asakawa, A. Arai, M. Oshima, T. Kasugai, K. Kamada, K. Suzuki, H. Tanaka, F. Tominaga, K. Futagami, S. Hojo, M. Mihara, H. Higuchi, K. Kusano, M. Arisawa, T. Kato, M. Joh, T. Mochida, S. Enomoto, N. Shimosegawa, T. Koike, K. Evidence-based clinical practice guidelines for functional dyspepsia 2021. 2022, 47-61. https://doi.org/10.1007/s00535-021-01843-7
4. Masuy, I. Van Oudenhove, L. Tack, J. Review article: treatment options for functional dyspepsia. 2019, 1134-1172. https://doi.org/10.1111/apt.15191
5. Xie, Y. Bowe, B. Li, T. Xian, H. Yan, Y. Al-Aly, Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. 2017, 1482-1494. doi: 10.1016/j.kint.2016.12.021.
6. Song, TJ. Kim, J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. 2019, e0216750. DOI: 10.1371/journal.pone.0216750.
7. Haastrup, PF. Thompson, W. Sondergaard, J. Jarbol, DE. Side effects of long-term proton pump inhibitor use: A review. 2018, 114-121. doi: 10.1111/bcpt.13023.
8. Jaynes, M. Kumar, AB. The risks of long-term use of proton pump inhibitors: a critical review. 2019, 1-13. DOI: 10.1177/2042098618809927.
9. Kinoshita, Y. Ishimura, N. Ishihara, S. Advantages and disadvantages of long-term proton pump inhibitor use. 2018, 182-196. doi: 10.5056/jnm18001
10. Miller, JW. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: clinical implications. 2018, 511S-518S. https://doi.org/10.1093/advances/nmy023
11. Singh, A. Cresci, GA. Kirby, DF. Proton pump inhibitors: risks and rewards and emerging consequences to the gut microbiome. 2018, 614-624. doi: 10.1002/ncp.10181
12. Linder, L. Tamboue, C. Clements, JN. Drug-induced vitamin B12 deficiency: A focus on proton pump inhibitors and histamine-2 antagonists. 2017, 639-642. DOI: 10.1177/0897190016663092.
13. Nehra, AK. Alexander, JA. Loftus, CG. Nehra, V. Proton pump inhibitors: review of emerging concerns. 2018, 240-246. https://doi.org/10.1016/j.mayocp.2017.10.022.
14. Eusebi, LH. Rabitti, S. Artesiani, ML. Gelli, D. Montagnani, M. Zagari, RM. Bazzoli, F. Proton pump inhibitors: risks of long-term use. 2017, 1295-1302. DOI: 10.1111/jgh.13737
15. Ortiz-Guerrero, G. Amador-Munoz, D. Calderon-Ospina, CA. Lopez-Fuentez, D. Mesa, MON. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. 2018, 1-9. DOI: 10.1155/2018/5257285
16. Rodriguez-Poncelas, A. Barcelo, MA. Saez, M. Coll-de-Tuero, G. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort. 2018, 1-16. https://doi.org/10.1371/journal.pone.0204231
17. Thong BKS, Ima-Nirwana S, Chin KY. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. Int J Environ Res Public Health. 2019 May 5;16(9):1571. doi: 10.3390/ijerph16091571. PMID: 31060319; PMCID: PMC6540255.
18. Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019 Mar 11;12:1756284819834511. doi: 10.1177/1756284819834511. PMID: 30886648; PMCID: PMC6415482.